Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.ijcard.2010.02.017
DC FieldValue
dc.titleComparison between fixed-dose, intracoronary bolus-only versus standard weight-adjusted dose, intravenous bolus and infusion administration of abciximab in patients undergoing primary percutaneous coronary intervention
dc.contributor.authorLee, C.-H.
dc.contributor.authorNgo, H.M.
dc.contributor.authorSewianto, A.
dc.contributor.authorNguyen, T.H.
dc.contributor.authorLee, J.
dc.contributor.authorTeo, S.-G.
dc.contributor.authorLow, A.F.
dc.contributor.authorTan, H.-C.
dc.date.accessioned2011-09-27T05:16:57Z
dc.date.available2011-09-27T05:16:57Z
dc.date.issued2010
dc.identifier.citationLee, C.-H., Ngo, H.M., Sewianto, A., Nguyen, T.H., Lee, J., Teo, S.-G., Low, A.F., Tan, H.-C. (2010). Comparison between fixed-dose, intracoronary bolus-only versus standard weight-adjusted dose, intravenous bolus and infusion administration of abciximab in patients undergoing primary percutaneous coronary intervention. International Journal of Cardiology 145 (2) : 355-357. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ijcard.2010.02.017
dc.identifier.issn01675273
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/26916
dc.description.abstractWe studied the safety and effectiveness of fixed-dose, intracoronary bolus-only abciximab in 195 patients who underwent primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. The patients were divided into 2 groups: Group A (n = 120, 61.5%) received fixed-dose, intracoronary bolus-only, abciximab 10 mg; and Group B (n = 75, 38.5%) received standard intravenous bolus (0.25 mg/kg) and maintenance abciximab infusion of 0.125 μg/kg/min for 12 h. There was no statistically significant difference in the baseline and post-procedure TIMI flow between Groups A and B. Final TIMI 3 flow was achieved in 90.0% and 89.3% of the patients in Groups A and B, respectively (p = 0.14). Final TIMI myocardial perfusion grade 2/3 was achieved in 92.5% and 96.0% of the patients in Groups A and B, respectively (p = 0.45). The six-month clinical outcomes were similar between Groups A and B (8.3% versus 5.3%, p = 0.62). © 2010 Elsevier Ireland Ltd. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.ijcard.2010.02.017
dc.sourceScopus
dc.subjectAbciximab
dc.subjectBolus
dc.subjectST-segment elevation myocardial infarction
dc.typeOthers
dc.contributor.departmentMEDICINE
dc.description.doi10.1016/j.ijcard.2010.02.017
dc.description.sourcetitleInternational Journal of Cardiology
dc.description.volume145
dc.description.issue2
dc.description.page355-357
dc.identifier.isiut000284949900101
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

3
checked on Sep 13, 2019

WEB OF SCIENCETM
Citations

3
checked on Sep 5, 2019

Page view(s)

270
checked on Sep 9, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.